Tumor Glycomics

SRI operates one of seven National Cancer Institute (NCI) funded Tumor Glycome Laboratories. These laboratories are the principal component of the trans-NIH Alliance of Glycobiologists for Detection of Cancer and Cancer Risk, which is searching for glycan-based biomarkers for breast, ovarian, lung, prostate, and pancreatic cancers and melanoma.

SRI's research team includes investigators with established records in

  • High-throughput platforms of carbohydrate microarrays

  • Neoglycolipid (NGL) technology coupled with mass spectrometry for carbohydrate ligand discovery

  • Flow cytometry (Hi-D FACS) for highly sensitive detection of cell and serum markers

  • The first international standard for detection of serum prostate-specific antigen (PSA)

SRI’s thrust is identification and characterization of carbohydrate-based immunological markers of human cancers, as well as development of highly sensitive assays for clinical and research applications.

Current research focuses on glycan markers of prostate cancers and anti-glycan autoantibody signatures in prostate cancer patients.

 

Divisions, Centers + Labs